A vaccine comprising an immunologically effective amount of recombinant modified vaccinia Ankara (rMVA) virus which is genetically stable after serial passage and produced by a) constructing a transfer plasmid vector comprising a modified H5 (mH5) promoter operably linked to a DNA sequence encoding a heterologous foreign protein antigen, wherein the expression of said DNA sequence is under the control of the mH5 promoter; b) generating rMVA virus by transfecting one or more plasmid vectors obtained from step a) into wild type MVA virus; c) identifying rMVA virus expressing one or more heterologous foreign protein antigens using one or more selection methods for serial passage; d) conducting serial passage; e) expanding an rMVA virus strain identified by step d); and f) purifying the rMVA viruses from step e) to form the vaccine. One embodiment is directed to a fusion cytomegalovirus (CMV) protein antigen comprising a nucleotide sequence encoding two or more antigenic portions of Immediate-Early Gene-1 or Immediate-Early Gene-2 (IEfusion), wherein the antigenic portions elicit an immune response when expressed by a vaccine.

The present invention relates to an oncolytic vaccinia virus and virus vectors for use in cancer therapy where in the virus comprises at least three vaccinia virus promoters which are positioned in the same orientation.

The present invention relates to an oncolytic vaccinia virus and virus vectors for use in cancer therapy where in the virus comprises at least three vaccinia virus promoters which are positioned in the same orientation.

Disclosed herein are methods of treating or preventing a myeloproliferative disease, a cancer, or a cardiovascular disease, and methods of inducing an immune response, in a subject having a JAK2V617F substitution and/or a CALR exon 9 mutation.

Disclosed herein are methods of treating or preventing a myeloproliferative disease, a cancer, or a cardiovascular disease, and methods of inducing an immune response, in a subject having a JAK2V617F substitution and/or a CALR exon 9 mutation.

Intact, non-replicating or replication-deficient poxvirus acts as an adjuvant when administered with mechanical disruption, with or without a T cell antigen. Compositions and methods for inducing T cell mediated immune responses to antigen in epithelial tissues of a subject are provided.

Intact, non-replicating or replication-deficient poxvirus acts as an adjuvant when administered with mechanical disruption, with or without a T cell antigen. Compositions and methods for inducing T cell mediated immune responses to antigen in epithelial tissues of a subject are provided.

The invention relates to a pharmaceutical combination and related methods for reducing tumor volume and/or increasing the survival of a cancer patient. The combination comprises an intravenous administration of a recombinant MVA encoding a tumor-associated antigen and an administration of an antibody to a cancer patient.

The invention relates to a pharmaceutical combination and related methods for reducing tumor volume and/or increasing the survival of a cancer patient. The combination comprises an intravenous administration of a recombinant MVA encoding a tumor-associated antigen and an administration of an antibody to a cancer patient.

The present disclosure describes methods, compositions, and kits related to the combination of a TLR7 modulating compound and an HIV vaccine. The combination can be used in a method of treating or preventing an HIV infection in a human.